Skip to main content
OpenTrials
Completed

NCT Number: NCT04582331

Improving Real-time COVID-19 Monitoring Through Smartphone Voice Analysis

This is a confirmatory study that seeks to examine whether respiratory-responsive vocal biomarkers have potential to respond to COVID-19 infection status and respiratory symptom severity. Patients with suspected COVID-19 and healthy controls will submit daily voice samples and symptom inventories on their personal smartphone devices for 14 days.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Deenanath Mangeshkar Hospital & Research Centre, Pune, India

Loading trial locations.

About this study

This is an observational study examining the potential to use voice analysis to aid in the identification of COVID-19 and as an aid to monitoring of respiratory symptoms of COVID-19. Patients with suspected COVID-19 and healthy controls will be enrolled and use their own smartphone device to provide daily voice samples and symptom inventories. This study seeks to confirm and extend findings from preliminary data from patients with asthma, COPD and cough that has indicated the potential of respiratory responsive vocal biomarkers (RRVB) to respond to respiratory diagnoses and symptom severity. The same RRVB will be examined to confirm whether this potential generalizes to respiratory symptoms associated with COVID-19

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Own an eligible smartphone (iOS or Android) that is able to download and run the Sonde Health app (access to smartphone provided by parent or legal guardian of participants under the age 18 is allowed)
  • Willing to sign up for a Sonde app account
  • Agreement with the subject consent information presented on the Sonde app. In case of adolescent subjects, agreement with subject consent information provided by a parent or legal guardian
  • Stated willingness and ability to comply with all study procedures for the duration of the study
  • Male or female, aged 12 or above (including adults)
  • Able to read and speak English or Spanish (required to follow app instructions and provide correct voice elicitations)
  • Pregnant women are allowed to participate

For suspected COVID-19 patients:

  • Confirmed or suspected COVID-19 infection with mild or severe illness severity at screening on Day 1
  • Suspected COVID-19 includes patients having at least one of the following symptoms that are present at most 10 days prior to enrollment:
  • Cough
  • Fever (>37.5 C/ 99.5 F)
  • Shortness of breath
  • Sore throat
  • Diarrhea
  • Anosmia
  • Loss of taste/ ageusia
  • COVID-19 viral test ordered at the study site within at most 5 days prior to or on Day 1

For healthy volunteers:

  • Hospital staff or co-living family members, or co-living family member of a COVID-19 positive patient that is enrolled in this study
  • Age 12 and above

Exclusion criteria

  • Difficulties with speech production
  • Difficulties reading or responding to instructions and questions on a smartphone screen
  • Critical COVID-19 illness severity at screening on Day 1
  • Other critical health condition where study participation would place unreasonable burden or risk on the patient as determined by the study site principal investigator

For healthy volunteers:

  • History of positive COVID-19 viral or serologic test result any time prior to enrollment
  • Any hospital staff that is a member of the study team, and staff in the pulmonary and infectious disease departments of the participating institution, or any of their co-living family members

Treatment and study plan

Smartphone-based voice and self-reported symptom collection

Other

Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study

Primary outcomes

  1. Vocal biomarker performance in COVID-19 positive vs. healthy controls

    Time frame: Day 1 of study enrollment

    Sensitivity, Specificity and Diagnostic Odds Ratio of RRVB, either alone or in combination with a symptom inventory, to identify COVID-19 positive patients vs. asymptomatic healthy controls

Secondary outcomes

  1. Vocal biomarker vs. symptom burden correlation in COVID-19 positive

    Time frame: Pooled across study Days 1-14

    Mean and 90% confidence interval of the correlation coefficient distribution between RRVB-based scores and self-reported respiratory symptom burden pooled across study days within individual COVID-19 patients

  2. Vocal biomarker performance in COVID-19 positive vs. COVID-19 negative symptomatic

    Time frame: Day 1 of enrollment

    Sensitivity, Specificity and Diagnostic Odds Ratio of RRVB, either alone or in combination with a symptom inventory, to discriminate COVID-19 positive vs. symptomatic COVID-19 negative patients on Day 1

Sponsors and collaborators

Lead sponsor

Sonde Health

Industry

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Oct 9, 2020
Registry last updated
May 14, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.